Information Provided By:
Fly News Breaks for December 22, 2015
DRNA
Dec 22, 2015 | 07:30 EDT
Leerink analyst Michael Schmidt lowered his price target for Dicerna to $20 citing slower than expected pipeline progress. The company still has still not reached a maximum tolerated dose in either of two ongoing Phase I dose-escalation trials in "all comers" or hepatocellular carcinoma, Schmidt tells investors in a research note. He believes Dicerna's story is fundamentally intact, but notes both programs are advancing slowly. The analyst keeps an Outperform rating on the name.
News For DRNA From the Last 2 Days
There are no results for your query DRNA